DHA Supplementation for X-Linked Retinitis Pigmentosa (XLRP)


Description: The Retina Foundation of the Southwest (Dallas, Texas) is conducting an FFB-funded Phase II clinical trial of docosahexaenoic acid (DHA) for the treatment of males with XLRP. More than 50 males are in the trial which will conclude in 2012. Earlier clinical studies suggested that DHA might slow the progress of vision loss in people with XLRP. (Males were chosen for the study because they have more severe manifestations of XLRP.) DHA is an omega-3 fatty acid found in coldwater fish such as tuna, salmon, and mackerel.

Trial Status: Ongoing; not recruiting new participants.

DHA to be Studied as Treatment for X-Linked RP

Additional Information:
DHA clinical trial listing on ClinicalTrials.Gov